₹986.75
−1.12%NSE close, 16 Nov 2026
+14.08%
Aarti Pharmalabs is a small cap company in the Healthcare sector, listed on NSE under the symbol AARTIPHARM. At ₹986.75 a share, the market values the whole company at ₹8,948 crore.
In FY26, it reported sales of ₹1,819 crore and a net profit of ₹173 crore, an operating margin of 20.3%.
The market values the company at 35.4 times its profit over the last twelve months and 3.97 times its book value; its return on equity is 11.2% and its borrowings are 0.37 times its equity.
Promoters hold 39.66% of the shares, and have pledged 12.0% of their holding. Foreign institutions hold 8.15%, and domestic institutions, mutual funds among them, 8.40%.
Over the past year the share price has risen 16.9%, and it is 3.6% below its 52-week high.
Companies of a similar size in the same sector include Viyash Scientific, Yatharth Hospital & Trauma Care Services, Blue Jet Healthcare and Procter & Gamble Health.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
| Viyash Scientific | ₹236.38 | ₹10,439 cr | 44.9 | 7.3% | +133.00% | +9.21% |
| Yatharth Hospital & Trauma Care Services | ₹1,069.05 | ₹10,301 cr | 54.9 | 10.0% | +54.40% | +34.65% |
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 | 12.4% | +127.10% | −8.67% |
| Procter & Gamble Health | ₹5,595.50 | ₹9,288 cr | 24.5 |
The sad demise of Promoter and Chairman Emeritus of the Company.
Transcript
Link of Recording
Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 | 610 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 353 | 388 | 459 | 364 | 409 | 418 | 291 | 344 | 330 | 470 | 400 | 475 |
| Operating profit | 95.7 | 118 | 96.5 | 93.7 | 129 | 146 | 95.2 | 74.7 | 102 | 113 | 136 | 135 |
| Operating margin | 21.3% | 23.2% | 17.4% | 20.5% | 23.9% | 25.8% | 24.7% | 17.9% | 23.7% | 19.4% | 25.4% | 22.1% |
| Other income | 1.4 | 2.0 | 2.2 | 4.5 | 5.0 | −1.6 | 1.6 | 0.1 | −0.4 | 8.1 | 0.5 | 0.5 |
| Interest | 4.5 | 4.7 | 4.8 | 5.5 | 10.0 | 6.6 | 6.8 | 10.7 | 12.6 | 16.9 | 12.9 | 15.0 |
| Depreciation | 18.8 | 19.1 | 20.2 | 20.9 | 23.0 | 22.8 | 22.8 | 24.8 | 28.6 | 28.2 | 30.0 | 30.5 |
| Profit before tax | 73.8 | 95.8 | 73.7 | 71.8 | 101 | 115 | 67.3 | 39.3 | 58.0 | 76.2 | 93.7 | 88.1 |
| Tax | 21.1 | 30.5 | 18.2 | 17.2 | 26.6 | 26.3 | 16.0 | 10.8 | 14.9 | 20.6 | 24.9 | 23.5 |
| Net profit | 52.8 | 64.4 | 55.5 | 54.6 | 74.0 | 88.3 | 49.5 | 28.6 | 46.4 | 61.1 | 76.1 | 68.9 |
| EPS (₹) | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 | 5.29 | 6.74 | 8.40 | 7.88 |
₹ crore, financial years to March.
| Line | FY24 | FY25 | FY26 |
|---|---|---|---|
| Sales | 1,853 | 2,115 | 1,819 |
| Expenses | 1,467 | 1,651 | 1,450 |
| Operating profit | 386 | 464 | 369 |
| Operating margin | 20.8% | 22.0% | 20.3% |
| Other income | 4.9 | 10.1 | 9.8 |
| Interest | 17.2 | 26.9 | 46.9 |
| Depreciation | 73.2 | 86.9 | 104 |
| Profit before tax | 301 | 361 | 225 |
| Tax | 83.6 | 88.3 | 58.2 |
| Net profit | 220 | 272 | 173 |
| EPS (₹) | 23.94 | 30.06 | 19.27 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 1,558 | 1,757 | 1,990 | 2,125 | 2,255 |
| Borrowings | 214 | 264 | 396 | 686 | 836 |
| Total liabilities | 672 | 825 | 917 | 1,357 | 1,571 |
| Fixed assets | 923 | 1,015 | 1,104 | 1,336 | 1,466 |
| Investments | 35.5 | 0 | 29.2 | 194 | 204 |
| Cash and equivalents | 24.9 | 23.6 | 6.7 | 8.5 | 4.2 |
| Total assets | 2,231 | 2,582 | 2,906 | 3,482 | 3,826 |
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | 332 | 262 | 30.0 |
| From investing | −414 | −431 | −131 |
| From financing | 65.4 | 171 | 96.9 |
| Spent on fixed assets | −402 | −409 | −123 |
| Free cash flow | −70.5 | −147 | −93.2 |
Margins, returns, debt, tax and cash.
| Line | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net margin | 11.9% | 12.9% | 9.5% |
| Operating margin | 20.8% | 22.0% | 20.3% |
| Return on equity | 12.5% | 13.7% | 8.1% |
| Return on capital employed | 15.7% | 16.2% | 9.7% |
| Return on assets | 8.5% | 9.4% | 5.0% |
| Debt to equity | 0.15 | 0.20 | 0.32 |
| Interest coverage | 18.50 | 14.40 | 5.80 |
| Debt to assets | 0.10 | 0.14 | 0.20 |
| Current ratio | 1.94 | 2.01 | 1.49 |
| Quick ratio | 1.01 | 1.12 | 0.81 |
| Cash ratio | 0.03 | 0.01 | 0.01 |
| Asset turnover | 0.72 | 0.73 | 0.52 |
| Fixed asset turnover | 1.83 | 1.92 | 1.36 |
| Inventory turnover | 1.60 | 1.90 | 1.30 |
| Receivables turnover | 3.60 | 3.70 | 3.10 |
| Gross margin | 44.9% | 46.7% | 54.1% |
| Cash from operations to profit | – | 122.0% | 152.0% |
| Effective tax rate | 27.8% | 24.5% | 25.9% |
| 57.7% |
| +17.70% |
| −6.69% |
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 | 18.1% | +17.10% | +2.78% |
|---|
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
|---|
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 | 26.1% | +25.10% | +15.46% |
|---|
| Suven Life Sciences | ₹268.90 | ₹7,598 cr | n/a | -84.2% | +30.40% | +39.45% |
|---|
Appointment of Smt. Vibha Thakkar as Chief Financial Officer of the company w.e.f. October 31, 2026.
Resignation of Shri Piyush Lakhani as Chief Financial Officer of the company He will be relievedfrom the services of the Company with effect from the close of business hours on October 30, 2026.
The financial results for the period ended September 30, 2026.
Intimation of Revamp of the Company's Website
Grant of 850 Options.
Schedule of meet
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI Listing Regulations- Reconstitution of Committee of the Board of Directors
Updates on Change in Directorate